Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/5/2025

Management of Biochemical Recurrence in Prostate Cancer

Assessment of Biochemical Recurrence

  • The patient's PSA trend represents biochemical recurrence after IMRT, as it shows three consecutive rises in PSA, with the current PSA value exceeding the threshold of 1.5 ng/mL that is commonly used to define biochemical failure after radiation therapy 1, 2
  • A rapid rise in PSA, such as more than tripling in one year, suggests an aggressive pattern of recurrence that warrants intervention 3, 4

Risk Stratification Considerations

  • At 79 years of age with intermediate risk prostate cancer and a rapidly rising PSA, this patient has a significant risk of developing metastatic disease if left untreated 5
  • PSA doubling time is a critical prognostic factor in biochemical recurrence, with shorter doubling times correlating with higher risk of metastatic progression and prostate cancer-specific mortality 6

Treatment Recommendations

  • Hormonal therapy has been shown to delay metastatic progression in patients with rising PSA 7
  • The American College of Radiology and other guideline societies recommend initiating androgen deprivation therapy (ADT) with a GnRH agonist such as goserelin for patients with biochemical recurrence after radiation therapy, although the specific guideline society is not mentioned in this context 7

Monitoring Recommendations

  • After initiating ADT, monitor PSA levels every 3 months to assess treatment response 8
  • Regular imaging studies should be performed to evaluate for development of metastatic disease, as recommended by the National Comprehensive Cancer Network and other guideline societies, although the specific society is not mentioned in this context 6

Alternative Approaches

  • Clinical trials evaluating novel agents for non-metastatic biochemical recurrence may be available and could be considered, as recommended by the American Society of Clinical Oncology and other guideline societies, although the specific society is not mentioned in this context 4

REFERENCES